Unicycive Therapeutics, Inc.
UNCY · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | -0.10 | 0.01 | -0.00 |
| FCF Yield | -53.86% | -85.89% | -192.51% | -24.10% |
| EV / EBITDA | -0.77 | -0.41 | -0.44 | -0.83 |
| Quality | ||||
| ROIC | -391.48% | 692.93% | 6,812.08% | -53.37% |
| Gross Margin | 0.00% | 100.00% | 100.00% | 0.00% |
| Cash Conversion Ratio | 0.78 | 0.60 | 0.87 | 0.58 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | – | – | – |
| Free Cash Flow Growth | -56.58% | -16.88% | -170.07% | -297.26% |
| Safety | ||||
| Net Debt / EBITDA | 0.70 | 0.29 | 0.01 | 1.73 |
| Interest Coverage | -452.35 | -253.34 | -3,008.67 | -14.29 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |